Lundbeck Head of R&D denies allergy aspirations

Lundbeck's recently initiated recruitment of grass allergy sufferers for a phase I trial does not herald changing winds at the pharmaceutical firm – no allergy market conquest is in the cards, says Head of R&D at Lundbeck Johan Luthman.
Lundbeck's headquarters in Denmark | Photo: Lundbeck / PR
Lundbeck's headquarters in Denmark | Photo: Lundbeck / PR
by albert rønning-andersson, translated by daniel pedersen

It created ripples when it was recently uncovered that pharmaceutical firm Lundbeck is on the lookout for 36 grass allergy sufferers for a phase I study.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading